NCT06117085View on ClinicalTrials.gov

CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions
Thyroid Nodule (Benign)
Interventions
DEVICE

CellFX® Percutaneous Electrode (PE) System

Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology

Trial Locations (1)

Unknown

"Ospedale del Mare , ASLNA1 Centro"

All Listed Sponsors
lead

Pulse Biosciences, Inc.

INDUSTRY